Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
31
Recruiting, any sponsor type, condition "primary biliary cholangitis"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed106
31 trials
Showing 1 to 25, recently updated first.
- A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCAPivotal-lookingRecruiting
Cascade Pharmaceuticals, IncAcademic, hospital or other
NCT07282353 · 135 participants (planned) · Start Dec 1, 2025 · Primary completion Dec 9, 2027
Drug: 2mg CS0159; Placebo · For: Primary Biliary Cholangitis
Sites: Hefei, China; Beijing, China; Chongqing, China · 41 sites in all
- FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC TherapyPivotal-lookingRecruiting
Xijing Hospital of Digestive DiseasesAcademic, hospital or other
NCT07296458 · 132 participants (planned) · Start Dec 15, 2025 · Primary completion Dec 31, 2028
Drug: Fenofibrate; UDCA (Ursodeoxycholic acid) · For: Primary Biliary Cholangitis (PBC)
Sites: Guangzhou, China; Xi'an, China
- Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisPivotal-lookingRecruiting
Gilead SciencesGilead Sciences (GILD)
NCT06051617 · 402 participants (planned) · Start Sep 7, 2023 · Primary completion Aug 2030
Drug: Seladelpar; Placebo · For: Primary Biliary Cholangitis
Sites: Birmingham, Alabama; Phoenix, Arizona; Lancaster, California · 218 sites in all
- Fenofibrate in Patients With Primary Biliary Cholangitis (PBC)Pivotal-lookingRecruiting
Xijing Hospital of Digestive DiseasesAcademic, hospital or other
NCT06365424 · 117 participants (planned) · Start Apr 8, 2017 · Primary completion Apr 2027
Drug: Fenofibrate; UDCA · For: Primary Biliary Cholangitis
Sites: Xi'an, China
- Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic AcidPivotal-lookingRecruiting
Xijing Hospital of Digestive DiseasesAcademic, hospital or other
NCT02823366 · 104 participants (planned) · Start Jan 2016 · Primary completion Dec 2028
Drug: Fenofibrate; UDCA · For: Primary Biliary Cirrhosis
Sites: Xi'an, China
- Study of Seladelpar and Cilofexor in Participants With Primary Biliary CholangitisPivotal-lookingRecruiting
Gilead SciencesGilead Sciences (GILD)
NCT07841977 · 132 participants (planned) · Start Oct 1, 2026 · Primary completion Dec 2028
Drug: Seladelpar; PTM Seladelpar and 4 more · For: Primary Biliary Cholangitis
Sites: Colorado Springs, Colorado; Lakewood Rch, Florida; Atlanta, Georgia · 4 sites in all
- A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing CholangitisPivotal-lookingRecruiting
IpsenIndustry
NCT07387549 · 350 participants (planned) · Start May 14, 2026 · Primary completion Apr 30, 2031
Drug: Elafibranor · For: Primary Sclerosing Cholangitis
Sites: Chandler, Arizona; Phoenix, Arizona; Coronado, California · 231 sites in all
IpsenIndustry
NCT07556913 · 3 participants (planned) · Start Jul 29, 2026 · Primary completion Jan 31, 2039
Drug: Elafibranor · For: Pregnancy Related
Sites: Wilmington, North Carolina
- A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary CholangitisPivotal-lookingRecruiting
IpsenIndustry
NCT06016842 · 276 participants (planned) · Start Aug 31, 2023 · Primary completion May 31, 2029
Drug: Elafibranor · For: Primary Biliary Cholangitis (PBC)
Sites: Tucson, Arizona; Little Rock, Arkansas; Coronado, California · 198 sites in all
McMaster UniversityAcademic, hospital or other
NCT07341282 · 14 participants (planned) · Start Jun 17, 2026 · Primary completion Dec 2027
Drug: Placebo (blinded); Vancomycin (blinded) and 1 more · For: Ulcerative Colitis (UC); Primary Sclerosing Cholangitis (PSC)
Sites: Hamilton, Canada
University of BirminghamAcademic, hospital or other
NCT06286709 · 58 participants (planned) · Start Mar 27, 2024 · Primary completion Sep 30, 2027
Drug: Faecal Microbiota Transplant · For: Primary Sclerosing Cholangitis; Inflammatory Bowel Diseases
Sites: Birmingham, United Kingdom; London, United Kingdom; Oxford, United Kingdom · 5 sites in all
- Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA TherapyPivotal-lookingRecruiting
Zydus Therapeutics Inc.Industry
NCT07424677 · 90 participants (planned) · Start Aug 11, 2026 · Primary completion Jul 2028
Drug: Saroglitazar Magnesium 1 mg; Placebo · For: Primary Biliary Cholangitis
Sites: Lakewood Rch, Florida
Zydus Therapeutics Inc.Industry
NCT06825559 · 6 participants (planned) · Start Aug 5, 2025 · Primary completion Dec 31, 2026
Drug: Saroglitazar Magnesium 1 mg · For: Cholestatic Liver Disease
Sites: Indianapolis, Indiana
- Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical OutcomesPivotal-lookingRecruiting
Zydus Therapeutics Inc.Industry
NCT07216235 · 386 participants (planned) · Start Mar 24, 2026 · Primary completion Nov 2032
Drug: Saroglitazar magnesium 1 mg; Placebo · For: Primary Biliary Cholangitis
Sites: Marietta, Georgia; Indianapolis, Indiana; Houston, Texas
Brigham and Women's HospitalAcademic, hospital or other
NCT05835505 · 28 participants (planned) · Start Dec 12, 2023 · Primary completion May 1, 2027
Drug: BRS201; Placebo · For: Primary Sclerosing Cholangitis
Sites: Chestnut Hill, Massachusetts
Mayo ClinicAcademic, hospital or other
NCT06905054 · 80 participants (planned) · Start Apr 15, 2025 · Primary completion Mar 30, 2028
Drug: Fenofibrate (drug) · For: Primary Sclerosing Cholangitis; Liver Transplant, Complications; PSC and 1 more
Sites: Scottsdale, Arizona
University of MinnesotaAcademic, hospital or other
NCT06197308 · 28 participants (planned) · Start Mar 1, 2024 · Primary completion Mar 31, 2027
Drug: oral vancomycin and oral amoxicillin · For: Primary Sclerosing Cholangitis
Sites: Minneapolis, Minnesota
- A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)Pivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT07229911 · 134 participants (planned) · Start Jan 7, 2026 · Primary completion Apr 6, 2028
Drug: TAK-781; Placebo · For: Healthy Volunteers; Primary Sclerosing Cholangitis
Sites: Salt Lake City, Utah
Stanford UniversityAcademic, hospital or other
NCT05912387 · 15 participants (planned) · Start May 31, 2023 · Primary completion May 31, 2027
Drug: Rosuvastatin · For: Primary Sclerosing Cholangitis; Inflammatory Bowel Diseases
Sites: Stanford, California
- Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary CholangitisPivotal-lookingRecruiting
Xijing Hospital of Digestive DiseasesAcademic, hospital or other
NCT05749822 · 104 participants (planned) · Start Feb 17, 2023 · Primary completion Dec 1, 2027
Drug: Fenofibrate 200mg; Placebo and 1 more · For: Primary Biliary Cholangitis
Sites: Beijing, China; Guangzhou, China; Zhengzhou, China · 12 sites in all
- Fenofibrate in Primary Biliary Cholangitis: a Real World StudyPivotal-lookingRecruiting
Xijing Hospital of Digestive DiseasesAcademic, hospital or other
NCT06755151 · 300 participants (planned) · Start Jan 17, 2024 · Primary completion Dec 2035
Drug: Fenofibrate · For: Primary Biliary Cholangitis (PBC)
Sites: Xi'an, China
- Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World StudyPivotal-lookingRecruiting
Xijing Hospital of Digestive DiseasesAcademic, hospital or other
NCT06755541 · 150 participants (planned) · Start Jan 30, 2024 · Primary completion Dec 2035
Drug: Fenofibrate in Combination With Ursodeoxycholic Acid · For: Primary Biliary Cholangitis (PBC)
Sites: Xi'an, China
- Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary CholangitisPivotal-lookingRecruiting
Xijing Hospital of Digestive DiseasesAcademic, hospital or other
NCT05751967 · 150 participants (planned) · Start Feb 22, 2023 · Primary completion Dec 1, 2027
Drug: Placebo Combined With Ursodeoxycholic Acid; Fenofibrate Combined With Ursodeoxycholic Acid · For: Primary Biliary Cholangitis
Sites: Lanzhou, China; Guangzhou, China; Nanjing, China · 7 sites in all
Elizabeth C. VernaAcademic, hospital or other
NCT06455280 · 8 participants (planned) · Start Sep 11, 2024 · Primary completion Dec 31, 2027
Drug: Siplizumab · For: Autoimmune Liver Disease; Liver Transplant Disorder; Autoimmune Hepatitis and 3 more
Sites: New York, New York
LISCure BiosciencesIndustry
NCT06699121 · 87 participants (planned) · Start Nov 2025 · Primary completion Mar 2028
Drug: LB-P8 low-dose; LB-P8 high-dose and 1 more · For: Primary Sclerosing Cholangitis (PSC)
Sites: Sacramento, California; Aurora, Colorado; Iowa City, Iowa · 7 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.